| Assay ID | Title | Year | Journal | Article |
|---|
| AID246857 | Effective dose for in vivo activity in D-GalN/LPS-induced rat hepatic injury model | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID7380 | Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID9098 | Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238965 | Inhibition of [3H]-PGE-2 binding to human prostanoid EP1 receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID237181 | Half life in dog after iv administration (n=2-3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID247519 | Inhibition of ADP-induced aggregation of human platelets | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID11998 | Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238480 | Inhibition of [3H]SQ-29,548 binding to human Prostanoid TP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID239139 | Displacement of [3H]PGE-2 from human Prostanoid EP1 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID239123 | Displacement of [3H]PGD-2 from human Prostanoid DP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID60970 | In vitro inhibition of ADP-induced platelet aggregation using dog platelet rich plasma | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238331 | Inhibition of [3H]-PGE-2 binding to Prostanoid EP3 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID12525 | Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID237182 | Half life in rat after iv administration (n=2-3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID10974 | Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238423 | Inhibition of [3H]-PGF-2 binding to human Prostanoid FP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID238330 | Inhibition of [3H]PGE-2 binding to Prostanoid EP2 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID239124 | Displacement of [3H]PGF-2 from human Prostanoid FP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID239037 | Inhibition of [3H]iloprost binding to human prostanoid IP receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID238938 | Inhibition of [3H]PGD-2 binding to human prostanoid DP receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID238966 | Inhibition of [3H]PGE-2 binding to human prostanoid EP2 receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID13662 | Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID271031 | Displacement of [3H]iloprost from cloned human PGI2 receptor | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID236688 | Maximal plasma concentration in rats after 0.32 mg/kg oral dose, n=3 | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID10679 | Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID9732 | Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238329 | Inhibition of [3H]PGE-2 binding to Prostanoid EP1 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID8339 | Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID239198 | Displacement of [3H]iloprost from human Prostanoid IP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID247512 | Inhibition of ADP-induced aggregation of rat platelets | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID92397 | In vitro inhibition of ADP-induced platelet aggregation using human platelet rich plasma | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID238968 | Inhibition of [3H]PGE-2 binding to human prostanoid EP4 receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID239141 | Displacement of [3H]PGE-2 from human Prostanoid EP3 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID8549 | Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID236685 | Maximal plasma concentration in dogs after 0.32 mg/kg oral dose, n=3 | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID236149 | Bioavailability of the drug after i.v. administration at a dose of 0.32 (mg/kg) in rat | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID9500 | Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID236706 | Maximum (Peak) plasma drug concentration after single-dose administration at a dose of 0.32 (mg/kg) in rat | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID247890 | In vitro inhibition of ADP-induced platelet aggregation in rat platelet rich plasma | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. |
| AID271030 | Agonist activity at rat PGI2 receptor assessed as inhibition of ADP-induced platelet aggregation | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID238422 | Inhibition of [3H]PGD-2 binding to human Prostanoid DP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID238332 | Inhibition of [3H]PGE-2 binding to Prostanoid EP4 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID236419 | Area Under Plasma concentration-time curve after peroral administration at a dose of 0.32 (mg/kg) in rat | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID239014 | Inhibition of [3H]SQ-29,548 binding to human prostanoid TP receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID236243 | Clearance in rat after iv administration (n=2-3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID247889 | In vitro inhibition of ADP-induced platelet aggregation in dog platelet rich plasma | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. |
| AID247525 | Inhibition of ADP-induced aggregation of monkey platelets | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID239140 | Displacement of [3H]-PGE-2 from human Prostanoid EP2 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID239181 | Displacement of [3H]SQ-29,548 from human Prostanoid TP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID237205 | Elimination half-life after peroral administration at a dose of 0.32 (mg/kg) in rat | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID160755 | In vitro Prostacyclin (PGI-2) receptor binding assay was determined based on displacement of [3H]iloprost radioligand from cloned human IP receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID271032 | Oral bioavailability in rat | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID247511 | Inhibition of ADP-induced aggregation of dog platelets | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID236092 | Bioavailability in dog at 0.32 mg/kg after po administration (n=3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID238689 | Ability to inhibit binding of [3H]iloprost to cloned human prostaglandin I2 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. |
| AID271029 | Agonist activity at human PGI2 receptor assessed as inhibition of ADP-induced platelet aggregation | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID238939 | Inhibition of [3H]PGF-2 binding to human prostanoid FP receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID13083 | Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v. | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID247935 | In vitro inhibition of ADP-induced platelet aggregation in human platelet rich plasma | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. |
| AID238503 | Inhibition of [3H]-Iloprost binding to human Prostanoid IP receptor | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| AID271035 | Cmax in rat at 0.32 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID238967 | Inhibition of [3H]PGE-2 binding to human prostanoid EP3 receptor | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID196104 | In vitro inhibition of ADP-induced platelet aggregation using rat platelet rich plasma | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
| AID236242 | Clearance in dog after iv administration (n=2-3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID239142 | Displacement of [3H]PGE-2 from human Prostanoid EP4 receptor | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
| Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
| AID236093 | Bioavailability in rat at 0.32 mg/kg after po administration (n=3) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
| AID271036 | AUC in rat at 0.32 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
| Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
| AID237350 | Total body clearance of drug from the plasma after i.v. administration at a dose of 0.32 (mg/kg) in rat | 2005 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
| Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |